The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata
Abstract
BACKGROUND: Optimal timing of antiretroviral therapy (ART) initiation for HIV-infected persons remains unclear. OBJECTIVE: To assess survival benefit of initiating ART at different CD4+ cell counts. DESIGN: Prospective observational study. SETTING: U.S. clinics in the HIV Outpatient Study (HOPS). PATIENTS: HIV-infected patients with CD4+ cell counts, plasma HIV RNA viral load, and ART use recorded from January 1994 through March 2002. MEASUREMENTS: Before initiation of ART, patients were grouped by their CD4+ cell counts into three subgroups: 0.201 to 0.350 x 10(9) cells/L (n = 399), 0.351 to 0.500 x 10(9) cells/L (n = 327), and 0.501 to 0.750 x 10(9) cells/L (n = 122). We compared mortality rates for each CD4+ subgroup among patients who initiated ART and patients who delayed ART until reaching a lower CD4+ subgroup. RESULTS: Mortality rates for 340 patients who initiated ART and 59 who delayed ART in the CD4+ subgroup of 0.201 to 0.350 x 10(9) cells/L were 15.4 and 56.4 deaths per 1000 person-years, respectively (rate ratio, 0.27 [95% CI, 0.14 to 0.55]; P < 0.001). For the CD4+ subgroup of 0.351 to 0.500 x 10(9) cells/L, mortality rates for 240 patients who initiated ART and 887 who delayed ART were 10.0 and 16.6 deaths per 1000 person-years, respectively (rate ratio, 0.61 [CI, 0.22 to 1.67]; P = 0.17). For the CD4+ subgroup of 0.501 to 0.750 x 10(9) cells/L, mortality rates in 55 patients who initiated ART and 67 who delayed ART were 7.5 and 3.1 deaths per 1000 person-years, respectively (rate ratio, 1.20 [CI, 0.17 to 8.53]; P > 0.2). Patients in the 0.201 to 0.350 x 10(9) cells/L and 0.351 to 0.500 x 10(9) cells/L CD4+ subgroups who initiated ART were more likely than those who delayed ART to achieve an undetectable HIV viral load (P = 0.03 and 0.04, respectively). CONCLUSIONS: Among HIV-infected persons with CD4+ cell counts of 0.201 to 0.350 x 10(9) cells/L, initiating ART is associated with reduced mortality compared with delaying such therapy. Survival benefits of earlier ART initiation (at CD4+ cell counts of 0.351 to 0.500 x 10(9) cells/L) are possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Self-citationFundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., & Snydman, D. R. (2001) · Clinical Infectious Diseases · doi:10.1086/318501 · Cited by 974
Hogg, R. S. (2001) · JAMA · doi:10.1001/jama.286.20.2568 · Cited by 728
Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 709
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
Schacker, T. W., Little, S. J., Connick, E., Gebhard, K. H., Zhang, Z., Krieger, J. N., Pryor, J., Havlir, D. V., Wong, J. K., Richman, D. D., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315178 · Cited by 146
Opravil, M., Ledergerber, B., Furrer, H., Hirschel, B. J., Imhof, A., Gallant, S., Wagels, T., Bernasconi, E., Meienberg, F., Rickenbach, M., et al. (2002) · AIDS · doi:10.1097/00002030-200207050-00009 · Cited by 111
Cited by
(2006) · PsycEXTRA Dataset · doi:10.1037/e545592006-001 · Cited by 2,958
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Palella, F. J., Baker, R. K., Moorman, A. C., Chmiel, J. S., Wood, K. C., Brooks, J. T., & Holmberg, S. D. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233310.90484.16 · Cited by 1,350
Self-citationEffect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Metadata
- Authors
- Palella, F. J., Deloria-Knoll, M., Chmiel, J. S., Moorman, A. C., Wood, K. C., Greenberg, A. E., Holmberg, S. D., & and the HIV Outpatient Study (HOPS) Investigators*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-04-15
- Volume
- 138
- Issue
- 8
- Pages
- 620-626
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2027863312
- Cited by
- 443
- References
- 8
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata. https://app.cochat.ai/papers/10.7326/0003-4819-138-8-200304150-00007
- The paper
- Palella, F. J., Deloria-Knoll, M., Chmiel, J. S., Moorman, A. C., Wood, K. C., Greenberg, A. E., Holmberg, S. D., & and the HIV Outpatient Study (HOPS) Investigators*. (2003). Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-8-200304150-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.